Cefamandole
From Wikipedia, the free encyclopedia
|
Cefamandole
|
|
| Systematic (IUPAC) name | |
| (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}- 3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo- 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
|
| Identifiers | |
| CAS number | 42540-40-9 (nafate) |
| ATC code | J01 |
| PubChem | |
| Chemical data | |
| Formula | C18H18N6O5S2 |
| Mol. mass | 462.505 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 75% |
| Metabolism | ? |
| Half life | 48 minutes |
| Excretion | Mostly renal, as unchanged drug |
| Therapeutic considerations | |
| Pregnancy cat. |
B1(AU) |
| Legal status | |
| Routes | Intramuscular, intravenous |
Cefamandole (INN, also known as cephamandole) is a broad-spectrum cephalosporin antibiotic. The clinically used form of cefamandole is the formate ester cefamandole nafate, a prodrug which is administered parenterally.
Cefamandole is no longer available in the United States.
|
||||||||||||||||||||

